In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Detailed price information for GE Healthcare Technologies Inc (GEHC-Q) from The Globe and Mail including charting and trades.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

As of 11 a.m. ET, shares of Novo ... earnings growth of about 19%, we may be approaching the point where all the "bad" news will be "priced in," and there's nowhere left for Novo Nordisk stock ...

Besides diabetes, obesity is a major risk factor for hypertension and heart disease, creating what can only be described as a ...

Ascendis positioned to drive rapid revenue growth COPENHAGEN ... waiting period for its collaboration agreement with Novo Nordisk, clearing the path for the development and commercialization ...

The Mexico-based hormone clinic, which has online capabilities is doing its part to meet increased global demand for ...